During the last session, Bioline Rx Ltd ADR (NASDAQ:BLRX)’s traded shares were 30.03 million, with the beta value of the company hitting 1.46. At the end of the trading day, the stock’s price was $0.26, reflecting an intraday gain of 19.44% or $0.05. The 52-week high for the BLRX share is $1.59, that puts it down -511.54 from that peak though still a striking 26.92% gain since the share price plummeted to a 52-week low of $0.19. The company’s market capitalization is $22.78M, and the average intraday trading volume over the past 10 days was 4.21 million shares, and the average trade volume was 1.10 million shares over the past three months.
Bioline Rx Ltd ADR (BLRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. BLRX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
Bioline Rx Ltd ADR (NASDAQ:BLRX) trade information
Bioline Rx Ltd ADR (BLRX) registered a 19.44% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 19.44% in intraday trading to $0.26, hitting a weekly high. The stock’s 5-day price performance is 9.51%, and it has moved by -12.29% in 30 days. Based on these gigs, the overall price performance for the year is -83.29%. The short interest in Bioline Rx Ltd ADR (NASDAQ:BLRX) is 1.06 million shares and it means that shorts have 2.39 day(s) to cover.
Bioline Rx Ltd ADR (BLRX) estimates and forecasts
Statistics show that Bioline Rx Ltd ADR has outperformed its competitors in share price, compared to the industry in which it operates. Bioline Rx Ltd ADR (BLRX) shares have gone down -51.76% during the last six months, with a year-to-date growth rate more than the industry average at 84.04% against 16.70.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.53%. While earnings are projected to return 91.44% in 2025.
BLRX Dividends
Bioline Rx Ltd ADR is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 0.82 million shares, is of CVI HOLDINGS, LLC’s that is approximately 1.126% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.46 million.
